TY - T1的头盔CPAP治疗的病人ith COVID-19 pneumonia: a multicentre cohort study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01935-2020 VL - 56 IS - 4 SP - 2001935 AU - Aliberti, Stefano AU - Radovanovic, Dejan AU - Billi, Filippo AU - Sotgiu, Giovanni AU - Costanzo, Matteo AU - Pilocane, Tommaso AU - Saderi, Laura AU - Gramegna, Andrea AU - Rovellini, Angelo AU - Perotto, Luca AU - Monzani, Valter AU - Santus, Pierachille AU - Blasi, Francesco Y1 - 2020/10/01 UR - //www.qdcxjkg.com/content/56/4/2001935.abstract N2 - Patients with coronavirus disease 2019 (COVID-19) pneumonia can develop hypoxaemic acute respiratory failure (hARF) with the need for positive end-expiratory pressure (PEEP). The administration of continuous positive airway pressure (CPAP) through a helmet improves oxygenation and avoids intubation [1, 2]. A European consensus document suggests that helmet CPAP should be the first therapeutic choice for hARF caused by COVID-19 pneumonia, mainly for minimising aerosol generation [3–5]. However, recommendations are based on experts' opinion and consider only evidence obtained in critically ill COVID-19 patients [3]. The Surviving Sepsis Campaign does not recommend the administration of CPAP for the initial management of severe COVID-19 [6].Helmet CPAP treatment fails in up to 44% of patients with moderate-to-severe hypoxaemic acute respiratory failure due to COVID-19 pneumonia https://bit.ly/3g7FAB8The authors would like to acknowledge the support of all the pulmonologists, respiratory fellows, nurses and respiratory physiotherapists of the COVID-19 HDUs of the Policlinico and Luigi Sacco Hospitals in Milan, Italy. ER -